FY2027 EPS Estimate for Janux Therapeutics Lifted by Analyst

Janux Therapeutics, Inc. (NASDAQ:JANX) – Research analysts at HC Wainwright boosted their FY2027 earnings per share estimates for shares of Janux Therapeutics in a research report issued to clients and investors on Tuesday, December 3rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($2.38) for the year, up from their prior estimate of ($2.48). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Janux Therapeutics’ FY2028 earnings at ($0.22) EPS.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. The business’s quarterly revenue was down 82.6% compared to the same quarter last year.

Several other equities research analysts have also commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research report on Thursday, November 7th. Stifel Nicolaus upped their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday. Wedbush restated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, UBS Group initiated coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective for the company. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $79.90.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $66.30 on Thursday. The stock’s 50 day moving average price is $50.21 and its 200 day moving average price is $45.96. Janux Therapeutics has a 1-year low of $7.79 and a 1-year high of $71.71. The company has a market cap of $3.48 billion, a PE ratio of -56.67 and a beta of 3.29.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $42.33, for a total transaction of $92,364.06. Following the transaction, the insider now owns 7,000 shares of the company’s stock, valued at $296,310. This trade represents a 23.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the sale, the chief executive officer now directly owns 307,054 shares of the company’s stock, valued at $14,219,670.74. This represents a 7.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 352,245 shares of company stock worth $17,032,336. Insiders own 29.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Franklin Resources Inc. raised its holdings in Janux Therapeutics by 64.5% in the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock valued at $937,000 after buying an additional 7,442 shares during the period. Virtu Financial LLC increased its holdings in Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after purchasing an additional 2,419 shares in the last quarter. Neo Ivy Capital Management acquired a new position in shares of Janux Therapeutics during the third quarter worth about $940,000. Geode Capital Management LLC boosted its position in shares of Janux Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after buying an additional 38,490 shares during the period. Finally, Barclays PLC grew its stake in shares of Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after buying an additional 144,883 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.